BLRX (BioLine Rx) ROC %: -49.96% (As of Mar. 2026)

What is BioLine Rx ROC %?

BioLine Rx BLRX -2.35% 23 ROC % is -49.96% as of Mar. 2026. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. BioLine Rx's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -49.96%.

As of today (2026-06-26), BioLine Rx's WACC % is 11.00%. BioLine Rx's ROC % is -50.83% (calculated using TTM income statement data). BioLine Rx earns returns that do not match up to its cost of capital. It will destroy value as it grows.

BioLine Rx (NAS:BLRX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BioLine Rx's WACC % is 11.00%. BioLine Rx's ROC % is -50.83% (calculated using TTM income statement data). BioLine Rx earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

BioLine Rx ROC % Related Terms

BioLine Rx ROC % Historical Data

* Premium members only.

The historical data trend for BioLine Rx's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx ROC % Chart

BioLine Rx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-89.63

-107.91

-118.67

-59.25

-47.46

BioLine Rx Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-50.20	-46.26	-44.21	-61.98	-49.96

23GF Score

BioLine Rx Ltd BLRX

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BioLine Rx ROC % Calculation

BioLine Rx's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-10.287 * ( 1 - 0% )	/	( (18.925	+	24.421)	/ 2 )
=	-10.287	/	21.673
=	-47.46 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.906	-	8.283	-	( 19.562	-	max(0, 15.406	-	27.104	+	19.562	))
=	18.925

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	40.905	-	4.926	-	( 20.876	-	max(0, 12.123	-	23.681	+	20.876	))
=	24.421

BioLine Rx's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-12.016 * ( 1 - 0% )	/	( (24.421	+	23.685)	/ 2 )
=	-12.016	/	24.053
=	-49.96 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	40.905	-	4.926	-	( 20.876	-	max(0, 12.123	-	23.681	+	20.876	))
=	24.421

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.797	-	7.154	-	( 17.353	-	max(0, 13.624	-	21.582	+	17.353	))
=	23.685

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -49.96% mean?

BioLine Rx (BLRX) has a ROC % of -49.96% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on BioLine Rx and its competitors.

Is BioLine Rx's ROC % too high?

BioLine Rx's current ROC % is -49.96%. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.

How does BioLine Rx's ROC % compare to VRTX and REGN?

BioLine Rx's ROC % of -49.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on BioLine Rx and its competitors. BioLine Rx's current ROC % is -49.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BioLine Rx stock overvalued right now?

BioLine Rx (BLRX) has a current ROC % of -49.96%. The current ROC % is -49.96%. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For BioLine Rx (BLRX), the current ROC % is -49.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Industry Healthcare Biotechnology

Comparable Companies XTAE:CBI XTAE:BOLT XTAE:EVGN XTAE:CANF XTAE:PPBT XTAE:XTLB XTAE:HDST-M XTAE:MTLF XTAE:GFC-M VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX

Other Exchanges BLRX:Israel YP2:Germany

Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website https://www.biolinerx.com

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

23GF Score

Get the complete analysis for BLRX

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.07

Price

View BLRX Analysis

See ROC % data for all stocks →